Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
05/2003
05/15/2003WO2003039541A1 4-[3,5-bis-(2-hydroxy-phenyl)-[1,2,4]triazol-1-yl]-benzoic acid derivatives for treating an excess of metal in the body
05/15/2003WO2003039535A1 Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
05/15/2003WO2003039528A1 Pharmaceutical composition comprising an adenosine a1/a2 agonist and a sodium hydrogen exchanger inhibitor
05/15/2003WO2003039524A1 Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder
05/15/2003WO2003039523A2 OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES
05/15/2003WO2003039480A2 Method of treating disorder related to high cholesterol concentration
05/15/2003WO2003039473A2 Method for treating or preventing inflammatory diseases
05/15/2003WO2003039472A2 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
05/15/2003WO2003039460A2 Mitotic kinesin inhibitors
05/15/2003WO2003039452A2 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
05/15/2003WO2003039451A2 Thiazole pyridazinones as adenosine antagonists
05/15/2003WO2003039446A2 Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase
05/15/2003WO2003039440A2 Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage
05/15/2003WO2003039439A2 Deuterated pyrazolopyrimidinones and drugs containing said compounds
05/15/2003WO2003039434A2 Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and products thereof
05/15/2003WO2003039344A2 Methods and compositions for correction of cardiac conduction disturbances
05/15/2003WO2003039342A2 Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
05/15/2003WO2003039341A2 Methods and compositions to treat cardiovascular disease using 139, 258, 1261, 1486, 2398, 2414, 7660, 8587, 10183, 10550, 12680, 17921, 32248, 60489 or 93804
05/15/2003WO2003039231A2 Compounds and methods for treating transplant rejection
05/15/2003WO2003009837A3 Treatment of vascular events in diabetics using lipid-modifying compositions
05/15/2003WO2003005965A3 Modulators of ceramidase and methods of use based thereon
05/15/2003WO2002097032A3 Proteins associated with cell growth, differentiation, and death
05/15/2003WO2002094856A3 Gpe analogs and peptidomimetics
05/15/2003WO2002083179A3 Fusion proteins
05/15/2003WO2002067961A3 Therapeutic uses of herbal compositions
05/15/2003WO2002058730A3 Compositions for treatment of ocular neovascularization
05/15/2003WO2002058720A3 Angiogenically effective unit dose of fgf-2 and method of use
05/15/2003WO2002058679A3 Antiangiogenic compounds and an assay for inhibitors of cell invasion
05/15/2003WO2002057298A3 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases
05/15/2003WO2002056027A3 Regulation of neutral development by daedalos
05/15/2003WO2002055108A9 Targeted modification of intracellular compounds
05/15/2003WO2002040654A3 A human serpin secreted from lymphoid cells lsi-01
05/15/2003WO2002040016A8 Association of calpain inhibitors and reactive oxygen species trapping agents
05/15/2003WO2002034285A3 Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
05/15/2003WO2002029031A3 Isoprenoid-dependent ras anchorage (idra) proteins
05/15/2003WO2002026781A9 Ige receptor antagonists
05/15/2003WO2002026717A8 Hydroxy acid integrin antagonists
05/15/2003WO2002000629A9 Iminopyrimidine nmda nr2b receptor antagonists
05/15/2003WO2002000611A8 Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists
05/15/2003US20030092917 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as portein kinase inhibitors
05/15/2003US20030092908 Autoimmune diseases; rheumatic diseases; multiple sclerosis; inflammatory bowel disease; immunosuppressants
05/15/2003US20030092891 Expressed ligand - vascular intercellular signalling molecule
05/15/2003US20030092771 Inhibitors of transcription factor NF-kappaB
05/15/2003US20030092762 Anti-inflammatory nitro and thia-fatty acids
05/15/2003US20030092748 Benzenesulfonamide derivatives and their use as MEK inhibitors
05/15/2003US20030092744 Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
05/15/2003US20030092736 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
05/15/2003US20030092732 Eating disorders; dietetics; antiinflammatory agents; autoimmune diseases
05/15/2003US20030092728 Antagonists of MCP-1 function and methods of use thereof
05/15/2003US20030092721 Antiinflammatory agents; rheumatic diseases
05/15/2003US20030092717 Inhibitors of p38 kinase
05/15/2003US20030092716 Antihypoxic agents
05/15/2003US20030092714 Heterocyclic inhibitors of ERK2 and uses thereof
05/15/2003US20030092713 Antiinflammatory agents; antiallergens; psychological disorders
05/15/2003US20030092708 Anticholesterol agents; cardiovascular disorders; antilipemic agents
05/15/2003US20030092703 Caspase inhibitors and uses thereof
05/15/2003US20030092702 Antiinflammatory agents; autoimmune disease; autoimmune diseases
05/15/2003US20030092697 Antidiabetic, antilipemic agents; cardiovascular disorders; anticancer agents
05/15/2003US20030092692 Alzheimer's and parkinson's disease
05/15/2003US20030092678 Muscle relaxants, controlling immunology, sexual disorders, rheumatic diseases
05/15/2003US20030092677 Glutamate receptor antagonists
05/15/2003US20030092655 Delivery system for nucleic acids
05/15/2003US20030092633 Preventing desensitization of receptors
05/15/2003US20030092631 IGF antagonist peptides
05/15/2003US20030092601 Microcompetition and human disease
05/15/2003US20030092180 Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
05/15/2003US20030092176 Ependymal neural stem cells and method for their isolation
05/15/2003US20030092163 Probiotic bifidobacterium strains
05/15/2003US20030092133 Interleukins-21 and 22
05/15/2003US20030092059 Human antibodies that bind human TNFalpha
05/15/2003US20030092054 Protein complexes and assays for screening anti-cancer agents
05/15/2003US20030091669 Mixture saponin, sugars and protein; solvent extraction, drying, sterilization; brain disorders, Alzheimer's disease
05/15/2003US20030091633 Pure form; cardiovascular disorders; side effect reduction
05/15/2003US20030091620 Transdermal drug delivery systems containing quaternary ammonium salts and methods of using the same
05/15/2003US20030091611 Antiproliferative agents ; antiinflammatory agents; insertable stent
05/15/2003US20030091567 Antiinflammatory agents; anticancer agents
05/15/2003US20030091549 Antiinflammatory agents; inflammatory bowel disease; gastrointestinal disorders
05/15/2003CA2789407A1 Inhibitor oligonucleotides and their use for specific repression of a gene
05/15/2003CA2669810A1 2-amino-thiazoline derivatives and their use as inhibitors of inducible no-synthase
05/15/2003CA2470271A1 Deuterated pyrazolopyrimidinones and drugs containing said compounds
05/15/2003CA2467853A1 Antibody stimulating il-1ra production
05/15/2003CA2466336A1 Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder
05/15/2003CA2466303A1 Selective targeting of apoptotic cells
05/15/2003CA2466232A1 Systems for delivery and release of angiotensin-(1-7)
05/15/2003CA2466198A1 Somatic cell derived embryonic stem cells and their differentiated progenies
05/15/2003CA2466033A1 Method of treating disorder related to high cholesterol concentration
05/15/2003CA2466030A1 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
05/15/2003CA2465945A1 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
05/15/2003CA2465894A1 Method for treating or preventing inflammatory diseases
05/15/2003CA2465713A1 Derivatives of phenoxy-n-'4-(1,1-dioxoisothiazolidin-2-yl)phenyl!-valeramide and other compounds as inhibitors of coagulation factor xa for the treatment of thromboembolic diseases and tumours
05/15/2003CA2465695A1 2-amino-thiazoline derivatives and their use as inhibitors of inducible no-synthase
05/15/2003CA2465491A1 Mitotic kinesin inhibitors
05/15/2003CA2465476A1 Methods and compositions for correction of cardiac conduction disturbances
05/15/2003CA2465416A1 Amine salts of an integrin receptor antagonist
05/15/2003CA2465364A1 Pharmaceutical composition comprising an adenosine a1/a2 agonist and a sodium hydrogen exchanger inhibitor
05/15/2003CA2465239A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
05/15/2003CA2465186A1 Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram
05/15/2003CA2465068A1 Quinazoline derivatives as antitumor agents
05/15/2003CA2464763A1 5-amidino-2-hydroxybenzenesulfonamide derivatives, medicinal compositions containing the same, medicinal use thereof and intermediates in the production thereof
05/15/2003CA2464717A1 Compounds and methods for treating transplant rejection
1 ... 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 ... 1595